Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

2.040 +0.180 (+9.68%)
Official Closing Price Updated: 4:15 PM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,285,403
Open 1.860
Bid (Size) 1.980 (1,400)
Ask (Size) 2.020 (100)
Prev. Close 1.860
Today's Range 1.822 - 2.045
52wk Range 1.200 - 3.560
Shares Outstanding 21,925,982
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
-17.1%
-17.1%
1 Month
+44.7%
+44.7%
3 Month
+38.8%
+38.8%
6 Month
-32.2%
-32.2%
1 Year
+63.2%
+63.2%

More News

Read More
News headline image
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Registration Momentum Builds Across the Oncology Pipeline
From USA News Group
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
From Acrivon Therapeutics, Inc
Via GlobeNewswire
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Acrivon Therapeutics, Inc. - Common Stock publicly traded?
Yes, Acrivon Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Acrivon Therapeutics, Inc. - Common Stock trade on?
Acrivon Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acrivon Therapeutics, Inc. - Common Stock?
The ticker symbol for Acrivon Therapeutics, Inc. - Common Stock is ACRV on the Nasdaq Stock Market
What is the current price of Acrivon Therapeutics, Inc. - Common Stock?
The current price of Acrivon Therapeutics, Inc. - Common Stock is 2.040
When was Acrivon Therapeutics, Inc. - Common Stock last traded?
The last trade of Acrivon Therapeutics, Inc. - Common Stock was at 07/08/26 04:15 PM ET
What is the market capitalization of Acrivon Therapeutics, Inc. - Common Stock?
The market capitalization of Acrivon Therapeutics, Inc. - Common Stock is 44.73M
How many shares of Acrivon Therapeutics, Inc. - Common Stock are outstanding?
Acrivon Therapeutics, Inc. - Common Stock has 45M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.